NEW YORK, April 7 (GenomeWeb News) - Shares of Orchid Cellmark were down 11.21 percent, or $.60, at $4.75 in mid-afternoon trading after the company reported that it will restate its earnings for the second and third quarters of 2005, and that it has received a delisting warning from the Nasdaq exchange for failing to file a financial statement on time.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.